Switch theme
Sign up to access all valuation multiples
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
1999
179
LTM Revenue $39.0M
LTM EBITDA $38.1M
$103M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Innate Pharma has a last 12-month revenue of $39.0M and a last 12-month EBITDA of $38.1M.
In the most recent fiscal year, Innate Pharma achieved revenue of $55.7M and an EBITDA of -$2.0M.
Innate Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Innate Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $53.3M | $55.7M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$13.2M | -$2.0M | XXX | XXX | XXX |
| EBITDA Margin | -25% | -4% | XXX | XXX | XXX |
| Net Profit | -$56.7M | -$62.4M | XXX | XXX | XXX |
| Net Margin | -107% | -112% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Innate Pharma's stock price is EUR 2 (or $2).
Innate Pharma has current market cap of EUR 146M (or $156M), and EV of EUR 95.9M (or $103M).
See Innate Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $103M | $156M | XXX | XXX | XXX | XXX | $-0.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Innate Pharma has market cap of $156M and EV of $103M.
Innate Pharma's trades at 2.6x LTM EV/Revenue multiple, and 2.7x LTM EBITDA.
Analysts estimate Innate Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Innate Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $103M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | -52.1x | XXX | XXX | XXX |
| P/E | -19.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpInnate Pharma's NTM/LTM revenue growth is 169%
Innate Pharma's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Innate Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Innate Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Innate Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -85% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 165% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 108% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 124% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Innate Pharma acquired XXX companies to date.
Last acquisition by Innate Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Innate Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Innate Pharma founded? | Innate Pharma was founded in 1999. |
| Where is Innate Pharma headquartered? | Innate Pharma is headquartered in France. |
| How many employees does Innate Pharma have? | As of today, Innate Pharma has 179 employees. |
| Who is the CEO of Innate Pharma? | Innate Pharma's CEO is Dr. Mondher Mahjoubi, M.D.. |
| Is Innate Pharma publicy listed? | Yes, Innate Pharma is a public company listed on PAR. |
| What is the stock symbol of Innate Pharma? | Innate Pharma trades under IPH ticker. |
| When did Innate Pharma go public? | Innate Pharma went public in 2006. |
| Who are competitors of Innate Pharma? | Similar companies to Innate Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Innate Pharma? | Innate Pharma's current market cap is $156M |
| What is the current revenue of Innate Pharma? | Innate Pharma's last 12-month revenue is $39.0M. |
| What is the current EBITDA of Innate Pharma? | Innate Pharma's last 12-month EBITDA is $38.1M. |
| What is the current EV/Revenue multiple of Innate Pharma? | Current revenue multiple of Innate Pharma is 2.6x. |
| What is the current EV/EBITDA multiple of Innate Pharma? | Current EBITDA multiple of Innate Pharma is 2.7x. |
| What is the current revenue growth of Innate Pharma? | Innate Pharma revenue growth between 2023 and 2024 was 5%. |
| Is Innate Pharma profitable? | Yes, Innate Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
